Medtronic (NYSE:MDT) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Medtronic (NYSE:MDT) posted its quarterly earnings data on Wednesday. The medical technology company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.01, FiscalAI reports. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.61 billion.

Medtronic Price Performance

MDT stock opened at $73.72 on Wednesday. The company has a market capitalization of $94.65 billion, a P/E ratio of 20.54, a price-to-earnings-growth ratio of 1.76 and a beta of 0.58. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic has a 52-week low of $73.31 and a 52-week high of $106.33. The business has a 50-day simple moving average of $82.11 and a two-hundred day simple moving average of $92.49.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were paid a dividend of $0.71 per share. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.9%. Medtronic’s payout ratio is 79.11%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Mizuho reduced their target price on Medtronic from $125.00 to $120.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Weiss Ratings downgraded Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, May 21st. Leerink Partners restated an “outperform” rating and issued a $119.00 target price on shares of Medtronic in a research note on Tuesday, March 10th. Jefferies Financial Group restated a “hold” rating and issued a $95.00 target price on shares of Medtronic in a research note on Thursday, April 23rd. Finally, Truist Financial reduced their target price on Medtronic from $103.00 to $95.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $106.45.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic beat fiscal Q4 estimates, with stronger-than-expected revenue and profit helping support the stock. Medtronic beats quarterly estimates on robust demand for heart devices
• Positive Sentiment: The company said fiscal 2026 revenue grew 8.4% and highlighted its strongest annual top-line growth in 10 years, which signals improving execution and demand across the portfolio. Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
• Positive Sentiment: Cardiac Ablation Solutions revenue jumped 78% globally, including 124% growth in the U.S., reflecting strong physician adoption of Affera technologies. Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera technologies broadens
• Positive Sentiment: Medtronic advanced its Hugo robotic surgery platform with new FDA filings and clearances, expanding the system’s potential use in general and gynecologic procedures and supporting long-term growth in surgical robotics. Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery system into general and gynecologic specialties in the United States
• Neutral Sentiment: Management also raised the quarterly dividend to $0.72 per share and maintained a strong cash-flow profile, which is supportive but not the main near-term driver of the stock. Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
• Neutral Sentiment: Analysts had expected solid results ahead of the report, so some of the recent move may reflect positioning into earnings rather than a new surprise. Medtronic to Report Fiscal Fourth Quarter Results; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
• Negative Sentiment: Despite the beat, investors appear to be looking past a softer outlook, suggesting the market still has concerns about the pace of future growth. Medtronic Stock Rises on Earnings. Wall Street Looks Past a Soft Outlook.

Hedge Funds Weigh In On Medtronic

A number of hedge funds have recently added to or reduced their stakes in MDT. Wellington Management Group LLP lifted its position in shares of Medtronic by 35.3% during the 3rd quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock worth $970,456,000 after buying an additional 2,658,981 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Medtronic by 68.3% during the 3rd quarter. AQR Capital Management LLC now owns 3,329,414 shares of the medical technology company’s stock worth $314,397,000 after buying an additional 1,350,888 shares in the last quarter. Lazard Asset Management LLC lifted its position in shares of Medtronic by 19.0% during the 3rd quarter. Lazard Asset Management LLC now owns 6,001,342 shares of the medical technology company’s stock worth $571,502,000 after buying an additional 957,149 shares in the last quarter. Schroder Investment Management Group lifted its position in shares of Medtronic by 12.5% during the 4th quarter. Schroder Investment Management Group now owns 8,468,982 shares of the medical technology company’s stock worth $813,530,000 after buying an additional 939,133 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Medtronic by 62.6% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,430,723 shares of the medical technology company’s stock worth $231,502,000 after buying an additional 935,941 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).